The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.本發明提供經分離之單株抗體(例如人類化及人類單株抗體)或其抗原結合片段，其以高親和力特異性結合於人類自然殺手細胞抑制性受體組2A (NKG2A)蛋白且展現治療所需之功能特性，諸如用以治療例如癌症。本發明亦提供包含本發明之抗NKG2A抗體的免疫結合物、雙特異性分子及醫藥組合物。另外本發明提供編碼該等抗體之核酸分子、表現載體、宿主細胞及使用該等抗體治療例如癌症之方法。本發明亦提供組合療法，其中本發明之抗NKG2A抗體與至少一種額外藥劑，諸如另一抗體(例如抗PD-1、抗PD-L1及/或抗CTLA-4抗體)共投與。
